Cannabis M&A Is Frozen. Employee Buyouts Are Giving Founders a Path Out — Without Selling Low

With strategic buyers scarce and PE keeping its distance from plant-touching companies, a growing number of cannabis operators are turning to ESOPs — and the tax math is hard to argue with.

The conventional exit story in cannabis has always worked like this: survive the early chaos, build a real business, wait for institutional capital to show up, and eventually a credible buyer writes a clean check. It is a reasonable plan. It has also not worked for most founders.

The buyer universe in cannabis is thin by any honest measure. Private equity — the primary source of acquisition capital in most industries — has largely avoided plant-touching companies because the risk-adjusted math does not close. There is no clear exit path, which means no LP committee is approving the deal. Large strategic buyers do exist, but they are working through their own capital constraints, which means acquisitions happen selectively, slowly, and almost never with the kind of terms a founder actually wants.

The result: founders who spent years building real businesses — real revenue, real social equity licensing bottlenecks with no obvious path out.

Why the Exit Market Is Broken

Three structural problems explain the freeze.

First, the 280E problem. Under current federal law, cannabis operators cannot deduct ordinary business expenses, which means their effective tax rate is punishing even in profitable years. A business generating $10 million in gross profit might pay federal taxes on most of it before a dollar flows to the owner. That steady cash bleed makes it hard for founders to wait around for market conditions to improve.

Second, the PE problem. Most private equity funds avoid plant-touching cannabis companies not because they doubt the economics but because they need a viable exit to close their own returns. Cannabis companies cannot be taken public the normal way. M&A activity is thin. And the legal and regulatory environment introduces risks that are difficult to model. The math does not work until something structural changes at the federal level — and that has been the case for years.

Third, the buyer terms problem. When buyers do show up, the terms are rarely clean. Seller financing, stock-in-the-buyer arrangements, earnouts tied to projections nobody believes — these are the tools buyers use to shift risk back to sellers. Founders who expected a real exit find themselves taking what amounts to a promise, not a payment.

What ESOPs Actually Are — and Why Cannabis Changes the Math

An Employee Stock Ownership Plan, in the cannabis context, works like this: an ownership trust is set up on behalf of a company’s employees, and the founder sells some or all of the business to that trust. The purchase is structured with cash at closing plus seller notes paid down from the company’s future cash flow. No outside buyer. No strategic acquirer absorbing the team into a larger platform.

The company keeps operating as its own entity. Leadership stays in place. The deal closes without requiring a buyer who shows up with clean capital — because the buyer is the trust, funded by the company itself over time.

That structure matters in any industry. In cannabis, it matters even more because of one specific tax provision.

A company that is 100% ESOP-owned becomes exempt from federal and state income tax. Fully exempt. In a sector where 280E has been quietly extracting 30 to 40 percent of gross profit from companies that cannot deduct basic operating expenses, the shift to an ESOP-owned structure redirects that cash back into the business. It can be used to pay down transaction debt, fund operations, or accelerate growth — rather than disappearing into the federal treasury.

That tax advantage changes the cash flow profile of the deal significantly. A business that was paying $2 to 4 million annually in 280E taxes suddenly has that cash available to service the transaction debt instead.

What Makes This Viable — and What Doesn’t

The ESOP structure is not a universal solution. A few conditions have to be in place for it to work.

The company needs an operating management team that can run the business after the founder steps back or reduces their role. Cannabis operations are knowledge-intensive — licensing, compliance, vendor relationships, local market dynamics — and much of that knowledge lives in people, not documents. If the only person who knows how to run the business is the founder, an ESOP transaction creates a leadership vacuum at the worst possible moment.

Founders also need realistic expectations about liquidity timing. Cash at closing is real but rarely covers the full purchase price. The balance comes in over time as the company pays down the notes. This is not a wired-to-your-account-by-Friday transaction.

And it requires a business with actual cash flow. The trust is financed by the company’s future earnings; if the underlying business is shaky, the structure collapses.

What This Says About the Broader Market

The growing interest in ESOPs among cannabis founders is a symptom of something bigger. The standard infrastructure that business owners in other industries take for granted — a competitive buyer pool, accessible debt markets, functional M&A activity — simply does not exist in cannabis yet. Operators have built real businesses in a structurally distorted environment, and now they are looking for exits in a market that was never built for them.

ESOPs are not a cure for a broken M&A market. They are a workaround. But for a founder who has built something real, has a leadership team that can run it, and does not want to hand the business over to a weak buyer on bad terms, the workaround is increasingly looking like the best option on the table.

The buyers will come eventually. Until they do, some founders are deciding not to wait.

Caleb Quinn covers the cannabis industry’s money flows, earnings, and deal landscape for CannabisInquirer.com.